EA201171212A1 - Замещенные производные 1-алкилциннолин-4(1h)-oha, их получение и их применение в терапии - Google Patents

Замещенные производные 1-алкилциннолин-4(1h)-oha, их получение и их применение в терапии

Info

Publication number
EA201171212A1
EA201171212A1 EA201171212A EA201171212A EA201171212A1 EA 201171212 A1 EA201171212 A1 EA 201171212A1 EA 201171212 A EA201171212 A EA 201171212A EA 201171212 A EA201171212 A EA 201171212A EA 201171212 A1 EA201171212 A1 EA 201171212A1
Authority
EA
Eurasian Patent Office
Prior art keywords
alk
group
therapy
alkylcinnolin
oha
Prior art date
Application number
EA201171212A
Other languages
English (en)
Inventor
Элоди Барбагалло
Кароль Леже
Мюриэлль Ринальди-Кармона
Паскаль Ру
Клод Верне
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051781&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201171212(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Санофи filed Critical Санофи
Publication of EA201171212A1 publication Critical patent/EA201171212A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Объектом настоящего изобретения являются соединения, соответствующие формуле (I), где Х означает двухвалентный (C-C)алкиленовый радикал, незамещенный или замещенный один или несколько раз группой Alk; Rозначает фенил, нафтил, пиридил, 1-бензотиенил или 1,3-бензодиоксолил; Rозначает атом водорода, атом галогена, группу Alk, группу OAlk или группу, выбранную из -S-Alk, -SO-Alk, -SO-Alk, -CO-N(R)-Alk, -N(R)SO-Alk, -N(R)CO-Alk, -N(R)SO-N(Alk); Rозначает атом водорода, атом галогена, группу Alk, группу OAlk; Rозначает атом водорода или (C-C)алкил; Alk означает (C-C)алкил, незамещенный или замещенный. Способ получения и применения в терапии.
EA201171212A 2009-04-07 2010-04-06 Замещенные производные 1-алкилциннолин-4(1h)-oha, их получение и их применение в терапии EA201171212A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0901696A FR2944013B1 (fr) 2009-04-07 2009-04-07 Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
PCT/FR2010/050657 WO2010116084A1 (fr) 2009-04-07 2010-04-06 Derives de 1-alkyl-cinnolin-4(1h)-one substitues, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
EA201171212A1 true EA201171212A1 (ru) 2012-04-30

Family

ID=41051781

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201171212A EA201171212A1 (ru) 2009-04-07 2010-04-06 Замещенные производные 1-алкилциннолин-4(1h)-oha, их получение и их применение в терапии

Country Status (20)

Country Link
US (1) US8420651B2 (ru)
EP (1) EP2417111B1 (ru)
JP (1) JP5651683B2 (ru)
KR (1) KR20120027212A (ru)
CN (1) CN102459195A (ru)
AR (1) AR076205A1 (ru)
AU (1) AU2010233590A1 (ru)
BR (1) BRPI1015951A2 (ru)
CA (1) CA2757859A1 (ru)
CL (1) CL2011002500A1 (ru)
CO (1) CO6440578A2 (ru)
EA (1) EA201171212A1 (ru)
FR (1) FR2944013B1 (ru)
IL (1) IL215512A0 (ru)
MA (1) MA33250B1 (ru)
MX (1) MX2011010650A (ru)
SG (1) SG175128A1 (ru)
TW (1) TW201040147A (ru)
UY (1) UY32548A (ru)
WO (1) WO2010116084A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022023550A2 (pt) 2020-05-19 2023-01-03 Bayer Cropscience Ag (tio)amidas azabicíclicas como compostos fungicidas
JP2023529475A (ja) 2020-06-10 2023-07-10 バイエル、アクチエンゲゼルシャフト 新規殺菌剤としてのアザビシクリル置換複素環

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306839A (en) * 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
WO2009053799A1 (en) * 2007-10-24 2009-04-30 Glenmark Pharmaceuticals, S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
FR2933697B1 (fr) * 2008-07-11 2010-08-13 Sanofi Aventis Derives de 1-benzyl-cinnolin-4-(1h)-one substitues, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AR076205A1 (es) 2011-05-26
US8420651B2 (en) 2013-04-16
US20120129864A1 (en) 2012-05-24
EP2417111A1 (fr) 2012-02-15
CN102459195A (zh) 2012-05-16
WO2010116084A1 (fr) 2010-10-14
MA33250B1 (fr) 2012-05-02
MX2011010650A (es) 2012-01-20
SG175128A1 (en) 2011-11-28
AU2010233590A1 (en) 2011-11-03
FR2944013B1 (fr) 2011-07-15
JP5651683B2 (ja) 2015-01-14
CL2011002500A1 (es) 2012-03-23
KR20120027212A (ko) 2012-03-21
JP2012522829A (ja) 2012-09-27
EP2417111B1 (fr) 2014-06-04
CA2757859A1 (fr) 2010-10-14
UY32548A (es) 2010-11-30
TW201040147A (en) 2010-11-16
CO6440578A2 (es) 2012-05-15
FR2944013A1 (fr) 2010-10-08
IL215512A0 (en) 2011-12-29
BRPI1015951A2 (pt) 2016-04-26

Similar Documents

Publication Publication Date Title
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
ATE552255T1 (de) 4-aminoindazole
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201200741A1 (ru) Способ получения этексилата дабигатрана
EA201170096A1 (ru) Замещенные производные пиримидона
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
EA201100447A1 (ru) Органические соединения
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
ECSP12012212A (es) Derivados de ariletinilo
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
ECSP099818A (es) Procesos para la preparacion de pirazoles
SMT201300085B (it) Composti di pirrolo
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
EA200900945A1 (ru) Новый способ синтеза агомелатина
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
EA201171000A1 (ru) Производные азаспиранилалкилкарбаматов в форме 5-членных гетероциклов, способ их получения и применение в терапии
MY159870A (en) Piperazine compound capable of inhibiting prostaglandin d synthase
CY1112829T1 (el) Νεα μεθοδος συνθεσης για την αγομελατινη
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
MA32956B1 (fr) Derives de 5-amino-2-(1-hydroxyethyl)-tetrahydropyrane
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
EA200700360A1 (ru) Новые производные амида гетероциклической карбоновой кислоты
EA201200866A1 (ru) Ингибиторы цистеиновых протеаз